ACB vs no Block for Pediatric ACL Reconstruction
The goal of this randomized controlled feasibility clinical trial is to assess the feasibility of conducting a randomized trial of adding a perioperative single-shot adductor canal block to standard of care general anesthesia compared to non-regional techniques in pediatric patients undergoing arthroscopic anterior cru
| Condition(s) | Anterior Cruciate Ligament, Anterior Cruciate Ligament (ACL) Tear |
|---|---|
| Status | Recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Summary | The goal of this randomized controlled feasibility clinical trial is to assess the feasibility of conducting a randomized trial of adding a perioperative single-shot adductor canal block to standard of care general anesthesia compared to non-regional techniques in pediatric patients undergoing arthroscopic anterior cruciate ligament (ACL) reconstruction. The main clinical question it aims to answer is does ACB result in improved Quality of Recovery-15 questionnaire scores on postoperative day 2 , postoperative day 14, and postoperative day 42. Secondary questions this study will address are will use of a single-shot adductor canal block result in: less total opioid consumption; shorter post anesthetic care unit (PACU) length of stay; better pain scores at rest and with movement at time of |
| Who can participate | Inclusion Criteria: * Patients ASA I, II and III * 10-18 years of age * scheduled for ACL reconstruction * agreeable to regional block and follow-ups Exclusion Criteria: * Contraindications to adductor canal block. * Patients with coagulopathies, preexisting neurologic deficit * Significant comorbidities that may impact recovery or interfere with the study. * Refusal to regional techniques. * Moderate to severe cognitive deficit (patients who are unable to complete the questionnaire) * Patients with history of malignant hyperthermia |
| Ages | 10 Years to 18 Years |
| Sex | All |
| Lead sponsor | Isabella Jaramillo |
| Locations | Hamilton, Ontario, Canada |
| Start date | 2025-07-01 |
| NCT ID | NCT06875427 |
| Official listing | https://clinicaltrials.gov/study/NCT06875427 |